Examination of the pancreas: Ductus Wirsungianus
Author: Prof. Dr. Christoph F. Dietrich
©Falk Foundation e.V., Freiburg. All rights reserved.
Vermeire S et al, Lancet Gastroenterol Hepatol. 2022;7(11):1024–35
ABX464 (Obefazimod) for moderate-to-severe active ulcerative colitis: In this phase 2b trial, all doses of ABX464 improved disease activity after 8 weeks significantly better than placebo.
Kårhus ML et al, Lancet Gastroenterol Hepatol. 2022;7(10):922–31
Liraglutid versus colesevelam for the treatment of bile acid diarrhea: In this pilot trial involving 52 patients, the glucagon-like peptide 1 receptor agonist liraglutide was superior to colesevelam in reducing stool frequency. Larger confirmatory trials powered for superiority are therefore warranted to establish liraglutide as novel treatment alternative.
El-Salhy M et al, Gastroenterology. 2022;163(4):982–94.e14
Efficacy of fecal microbiota transfer (FMT) for patients with irritable bowel syndrome: Results of a randomized trial of FMT after 2 and 3 years indicate that FMT results in high response rates and long-standing effects on dysbiosis with only few and mild self-limited adverse events.
Mantovani A et al, Gut 2023;72(2):372–80
Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: A recent meta-analysis shows that patients with NAFLD have a 1.5-fold higher long-term risk of new-onset heart failure, independent of diabetes, hypertension and other common cardiovascular risk factors.
Baiges A et al, J Hepatol. 2023;78(1):114–22
Recurrent thrombosis in people with non-cirrhotic splanchnic vein thrombosis: A current multicenter, retrospective observational study shows a significant risk of splanchnic and/or extrasplanchnic recurrent thrombosis in people with non-cirrhotic splanchnic vein thrombosis of idiopathic or local factor etiology. Splanchnic recurrent thrombosis can be asymptomatic and requires screening for its detection. Values of factor VIII ≥ 150% may help identify individuals at high risk of recurrent thrombosis who could benefit from long-term anticoagulation.
Hepatocellular carcinoma (HCC) in metabolic dysfunction-associated fatty liver disease (MAFLD): A recent Italian study shows that MAFLD alone or together with other etiologies is already responsible for > 70% of HCC cases. Despite a less favorable cancer stage at diagnosis, patients with MAFLD-associated HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
van Wanrooij RLJ et al, Endoscopy. 2022;54(11):1023–31
Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) versus duodenal stenting for malignant gastric outlet obstruction: EUS-GE had higher clinical success and lower stent dysfunction, with similar safety, compared with duodenal stenting, in a multicenter retrospective cohort study using propensity score-matching.
Kuipers T et al, Lancet Gastroenterol Hepatol. 2022;7(12):1103–11
Peroral endoscopic myotomy (POEM) versus pneumatic dilatation for treatment-naive patients with achalasia: Long-term results after 5 years of a randomized trial indicate that POEM has greater long-term efficacy with a low risk of major treatment-related complications compared to dilatation therapy.
Mukherjee S et al, Gastroenterology. 2022;163(5):1435–46.e3
Radiomics-based machine-learning models allows earlier diagnosis of pancreactic cancer: Radiomics-based machine learning models can detect pancreatic ductal adenocarcinoma (PDAC) from normal pancreas with a substantial lead time before clinical diagnosis. Prospective validation and integration of such models with complementary biomarkers has the potential for PDAC detection at a stage when surgical cure is still an option.
Inflammation of the Upper and Lower GI Tract: Common mechanisms and Treatments or Important Differences?
April 28 – 29, 2023, Bordeaux, France